Cencora, Inc. (COR)
Why Is Cencora (COR) Down 2.8% Since Last Earnings Report?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Here's Why Cencora (COR) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Walgreens Ready To Rebound?
Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments.
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Cencora (COR) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Cencora (COR) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Walgreens continues to shed stake in Cencora as it looks to bolster turnaround
Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround plan and pay down debt.
All You Need to Know About Cencora (COR) Rating Upgrade to Buy
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Pharma giant Cencora is alerting millions about its data breach
Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.
